tiprankstipranks
Xeris Pharmaceuticals (DE:2B30)
FRANKFURT:2B30
Germany Market
2B30
Xeris Pharmaceuticals
RESEARCH TOOLSreports

Xeris Pharmaceuticals (2B30) Ratios

0 Followers

Xeris Pharmaceuticals Ratios

DE:2B30's free cash flow for Q2 2026 was $0.86. For the 2026 fiscal year, DE:2B30's free cash flow was decreased by $ and operating cash flow was $-0.26. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
 1.45 2.19 1.67 1.64 2.54
Quick Ratio
 1.02 1.57 1.19 1.23 2.20
Cash Ratio
 0.64 1.01 0.71 0.71 1.66
Solvency Ratio
 -0.01 0.03 -0.12 -0.15 -0.27
Operating Cash Flow Ratio
 0.30 0.26 -0.37 -0.49 -1.40
Short-Term Operating Cash Flow Coverage
 0.89 4.59 -2.45 0.00 0.00
Net Current Asset Value
$ -146.88M$ -129.53M$ -185.01M$ -173.12M$ -112.52M
Leverage Ratios
Debt-to-Assets Ratio
 0.70 0.10 0.84 0.71 0.57
Debt-to-Equity Ratio
 -29.74 2.76 -9.17 -33.79 4.38
Debt-to-Capital Ratio
 1.03 0.73 1.12 1.03 0.81
Long-Term Debt-to-Capital Ratio
 1.05 0.70 1.16 1.04 0.81
Financial Leverage Ratio
 -42.32 28.02 -10.91 -47.57 7.62
Debt Service Coverage Ratio
 0.18 0.36 -0.24 -0.85 -4.81
Interest Coverage Ratio
 1.30 0.86 -1.01 -1.65 -5.81
Debt to Market Cap
 0.19 0.03 0.47 0.59 1.04
Interest Debt Per Share
 1.84 0.42 2.08 1.86 1.56
Net Debt to EBITDA
 10.22 -5.77 -14.28 -6.81 -1.10
Profitability Margins
Gross Profit Margin
83.34%81.70%81.86%82.52%79.47%
EBIT Margin
1.17%0.19%-13.11%-22.51%-74.36%
EBITDA Margin
4.89%4.36%-6.89%-14.48%-62.87%
Operating Profit Margin
10.91%8.53%-16.57%-26.85%-74.32%
Pretax Profit Margin
-5.12%0.19%-28.12%-38.74%-87.15%
Net Profit Margin
-5.12%0.19%-27.00%-37.98%-85.86%
Continuous Operations Profit Margin
-5.12%0.19%-27.00%-37.98%-85.86%
Net Income Per EBT
100.00%100.00%96.03%98.03%98.52%
EBT Per EBIT
-46.91%2.23%169.72%144.29%117.26%
Return on Assets (ROA)
-4.17%0.14%-16.97%-19.30%-27.48%
Return on Equity (ROE)
-426.33%4.05%185.16%917.94%-209.49%
Return on Capital Employed (ROCE)
16.46%9.09%-15.11%-19.35%-30.25%
Return on Invested Capital (ROIC)
12.51%8.89%-13.25%-18.68%-29.63%
Return on Tangible Assets
-5.60%0.20%-27.24%-32.77%-47.08%
Earnings Yield
-1.29%0.04%-11.02%-19.24%-52.48%
Efficiency Ratios
Receivables Turnover
 5.77 5.72 5.02 4.18 3.58
Payables Turnover
 5.98 17.36 16.08 2.48 4.91
Inventory Turnover
 0.69 0.78 0.76 0.74 0.92
Fixed Asset Turnover
 12.61 10.79 7.20 5.62 11.60
Asset Turnover
 0.81 0.76 0.63 0.51 0.32
Working Capital Turnover Ratio
 3.07 2.95 3.17 1.88 1.25
Cash Conversion Cycle
 530.94 512.11 527.36 434.80 426.67
Days of Sales Outstanding
 63.23 63.85 72.64 87.28 102.07
Days of Inventory Outstanding
 528.71 469.29 477.41 494.88 398.88
Days of Payables Outstanding
 61.00 21.02 22.69 147.36 74.28
Operating Cycle
 591.94 533.14 550.05 582.16 500.95
Cash Flow Ratios
Operating Cash Flow Per Share
 0.33 0.18 -0.25 -0.34 -0.76
Free Cash Flow Per Share
 0.32 0.17 -0.26 -0.36 -0.76
CapEx Per Share
 <0.01 <0.01 <0.01 0.02 <0.01
Free Cash Flow to Operating Cash Flow
 0.98 0.98 1.02 1.05 1.01
Dividend Paid and CapEx Coverage Ratio
 46.02 41.13 -42.60 -20.78 -196.36
Capital Expenditure Coverage Ratio
 46.02 41.13 -42.60 -20.78 -196.36
Operating Cash Flow Coverage Ratio
 0.20 0.76 -0.14 -0.21 -0.52
Operating Cash Flow to Sales Ratio
 0.17 0.10 -0.18 -0.29 -0.93
Free Cash Flow Yield
4.18%2.22%-7.61%-15.23%-57.33%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -78.99 2.24K -9.16 -5.20 -1.91
Price-to-Sales (P/S) Ratio
 3.95 4.32 2.45 1.97 1.64
Price-to-Book (P/B) Ratio
 -136.18 92.00 -16.80 -47.71 3.99
Price-to-Free Cash Flow (P/FCF) Ratio
 23.91 45.09 -13.15 -6.56 -1.74
Price-to-Operating Cash Flow Ratio
 23.42 43.99 -13.45 -6.88 -1.75
Price-to-Earnings Growth (PEG) Ratio
 <0.01 -22.22 0.52 0.15 0.03
Price-to-Fair Value
 -136.18 92.00 -16.80 -47.71 3.99
Enterprise Value Multiple
 90.89 93.32 -49.83 -20.45 -3.70
Enterprise Value
 1.49B 1.19B 697.39M 485.28M 256.48M
EV to EBITDA
 90.89 93.32 -49.83 -20.45 -3.70
EV to Sales
 4.45 4.06 3.43 2.96 2.33
EV to Free Cash Flow
 26.94 42.47 -18.43 -9.85 -2.48
EV to Operating Cash Flow
 26.35 41.43 -18.86 -10.32 -2.49
Tangible Book Value Per Share
 -0.67 -0.61 -1.03 -1.01 -0.72
Shareholders’ Equity Per Share
 -0.06 0.09 -0.20 -0.05 0.33
Tax and Other Ratios
Effective Tax Rate
 0.00 0.00 0.04 0.02 0.01
Revenue Per Share
 1.94 1.82 1.38 1.19 0.81
Net Income Per Share
 -0.10 <0.01 -0.37 -0.45 -0.70
Tax Burden
 1.00 1.00 0.96 0.98 0.99
Interest Burden
 -4.36 1.00 2.15 1.72 1.17
Research & Development to Revenue
 0.10 0.11 0.13 0.14 0.19
SG&A to Revenue
 0.62 0.62 0.81 0.00 0.00
Stock-Based Compensation to Revenue
 0.08 0.08 0.09 0.07 0.11
Income Quality
 -3.30 51.67 0.67 0.76 1.09
Currency in USD